Overview

Pilot Study Evaluating The Efficacy Of Etanercept In Acute Gout

Status:
Suspended
Trial end date:
2022-12-15
Target enrollment:
Participant gender:
Summary
The purpose of this pilot study is to investigate the safety and efficacy of etanercept (Enbrel™; Amgen) for the treatment of an acute gout attack will be non-inferior to triamcinolone acetonide an FDA approved drug to treat acute gout attacks.
Phase:
Phase 4
Details
Lead Sponsor:
Rutgers, The State University of New Jersey
Collaborator:
Amgen
Treatments:
Etanercept
Triamcinolone
Triamcinolone Acetonide
Triamcinolone diacetate
Triamcinolone hexacetonide